Details for Patent: 5,142,056
✉ Email this page to a colleague
Title: | Retroviral protease inhibiting compounds |
Abstract: | A retroviral protease inhibiting compound of the formula or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein X is a linking group; A is (1) substituted amino, (2) substituted carbonyl, (3) functionalized imino, (4) functionalized alkyl, (5) functionalized acyl, (6) functionalized heterocyclic or (7) functionalized (heterocyclic)alkyl; and B is (1) substituted carbonyl independently defined as herein, (2) substituted amino independently defined as herein, (3) functionalized imino independently defined as herein, (4) functionalized alkyl independently defined as herein, (5) functionalized acyl independently defined as herein, (6) functionalized heterocyclic independently defined as herein or (7) functionalized (heterocyclic)alkyl independently defined as herein. |
Inventor(s): | Kempe; Dale J. (Lake Villa, IL), Norbeck; Daniel W. (Lindenhurst, IL), Erickson; John W. (Barrington, IL) |
Assignee: | Abbott Laboratories (Abbott Park, IL) |
Filing Date: | May 09, 1990 |
Application Number: | 07/518,730 |
Claims: | 1. A compound of the formula: ##STR523## wherein R.sub.17 is 2-pyridinylmethyl, 3-pyridinylmethyl or 4-pyridinylmethyl and R.sub.800 is --O-- or --N(CH.sub.3)--; or a pharmaceutically acceptable salt, prodrug or ester thereof. 2. A compound selected from the group consisting of: (2S,3R,4R,5S)-2,5-Di-(N-((N-Methyl-N-((2-pyridinyl)methyl)amino)carbonyl)-v alinyl amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-Di-(N-((N-Methyl-N-((2-pyridinyl)methyl)amino)carbonyl)-v alinyl-amino)-3,4-dihydroxy-1,6-diphenylhexane; and (2S,3R,4S,5S)-2,5-Di-(N-((N-Methyl-N-((2-pyridinyl)methyl)amino)carbonyl)-v alinyl-amino)-3,4-dihydroxy-1,6-diphenylhexane; or a pharmaceutically acceptable salt, prodrug or ester thereof. 3. A compound selected from the group consisting of: (2S,3R,4R,5S)-2,5-Di-(N-((2-pyridinyl)methoxycarbonyl)valinyl-amino)-3,4-di hydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-Di-(N-((2-pyridinyl)methoxycarbonyl)valinyl-amino)-3,4-di hydroxy-1,6-diphenylhexane; and (2S,3R,4R,5S)-2,5-Di-(N-((2-pyridinyl)methoxycarbonyl)valinyl-amino)-3,4-di hydroxy-1,6-diphenylhexane; or a pharmaceutically acceptable salt, prodrug or ester thereof. 4. A compound selected from the group consisting of: (2S, 3R, 4S, 5S)-2,5-Di(N-((3-pyridinyl)methoxycarbonyl)-valinyl-amino)-3,4-dihydroxy-1 ,6-diphenylhexane; (2S, 3S, 4S, 5S)-2,5-Di(N-((3-pyridinyl)methoxycarbonyl)-valinyl-amino)-3,4-dihydroxy-1 ,6-diphenylhexane; and (2S, 3R, 4R, 5S)-2,5-Di(N-((3-pyridinyl)methoxycarbonyl)-valinyl-amino)-3,4-dihydroxy-1 ,6-diphenylhexane; or a pharmaceutically acceptable salt, prodrug or ester thereof. 5. (2S, 3R, 4S, 5S)-2,5-Di(N-((N-methyl)-N-((2-pyridinyl)-methyl)amino)carbonyl)-valinyl-a mino)-3,4-dihydroxy-1,6-diphenylhexane; or a pharmaceutically acceptable salt, prodrug or ester thereof. |